Skip to main content
Journal cover image

Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease.

Publication ,  Journal Article
Stuart, MJ; Chao, NS; Horning, SJ; Wong, RM; Negrin, RS; Johnston, LJ; Shizuru, JA; Long, GD; Blume, KG; Stockerl-Goldstein, KE
Published in: Biol Blood Marrow Transplant
2001

High-dose CBV (cyclophosphamide, carmustine, and etoposide) in combination with autologous HCT achieves survival rates of approximately 50% at 5 years in recurrent or refractory Hodgkin's disease (HD). However, carmustine (BCNU) dose-dependent pulmonary toxicity occurs in 20% to 30% of patients. A decreased incidence of interstitial pneumonitis as well as a possible benefit in efficacy has been reported with lomustine (CCNU) compared to BCNU in the standard dose setting. In a dose-escalation study, we substituted CCNU for BCNU in the CBV regimen for 16 patients with HD (n = 12) or non-Hodgkin's lymphoma (n = 4). Based on the promising results, an additional 47 consecutive patients with HD were treated with the following regimen: CCNU (15 mg/kg) orally on day -6, etoposide (60 mg/kg) intravenously on day -4, and cyclophosphamide (100 mg/kg) intravenously on day -2. Peripheral blood progenitor cells and/or bone marrow were infused on day 0. With a median follow-up for the surviving patients of 3.2 years (range, 0.8-9.9 years), the 3-year overall survival rate was 57% (CI, +/-15%), event-free survival was 52% (CI, +/-14%), and freedom from progression was 68% (CI, +/-14%). There were 21 deaths, 10 due to HD. Six patients died due to respiratory failure. Interstitial pneumonitis occurred in 63% of patients and could not be correlated with prior chest radiotherapy. This regimen demonstrated survival rates similar to those of historical studies that used the CBV regimen. However, the incidence of interstitial pneumonitis was in excess of expected.

Duke Scholars

Published In

Biol Blood Marrow Transplant

DOI

ISSN

1083-8791

Publication Date

2001

Volume

7

Issue

10

Start / End Page

552 / 560

Location

United States

Related Subject Headings

  • Transplantation, Autologous
  • Therapeutic Equivalency
  • Survival Rate
  • Stem Cell Transplantation
  • Salvage Therapy
  • Middle Aged
  • Maximum Tolerated Dose
  • Male
  • Lymphoma, Non-Hodgkin
  • Lung Diseases, Interstitial
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Stuart, M. J., Chao, N. S., Horning, S. J., Wong, R. M., Negrin, R. S., Johnston, L. J., … Stockerl-Goldstein, K. E. (2001). Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. Biol Blood Marrow Transplant, 7(10), 552–560. https://doi.org/10.1016/s1083-8791(01)70015-8
Stuart, M. J., N. S. Chao, S. J. Horning, R. M. Wong, R. S. Negrin, L. J. Johnston, J. A. Shizuru, G. D. Long, K. G. Blume, and K. E. Stockerl-Goldstein. “Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease.Biol Blood Marrow Transplant 7, no. 10 (2001): 552–60. https://doi.org/10.1016/s1083-8791(01)70015-8.
Stuart MJ, Chao NS, Horning SJ, Wong RM, Negrin RS, Johnston LJ, et al. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. Biol Blood Marrow Transplant. 2001;7(10):552–60.
Stuart, M. J., et al. “Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease.Biol Blood Marrow Transplant, vol. 7, no. 10, 2001, pp. 552–60. Pubmed, doi:10.1016/s1083-8791(01)70015-8.
Stuart MJ, Chao NS, Horning SJ, Wong RM, Negrin RS, Johnston LJ, Shizuru JA, Long GD, Blume KG, Stockerl-Goldstein KE. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. Biol Blood Marrow Transplant. 2001;7(10):552–560.
Journal cover image

Published In

Biol Blood Marrow Transplant

DOI

ISSN

1083-8791

Publication Date

2001

Volume

7

Issue

10

Start / End Page

552 / 560

Location

United States

Related Subject Headings

  • Transplantation, Autologous
  • Therapeutic Equivalency
  • Survival Rate
  • Stem Cell Transplantation
  • Salvage Therapy
  • Middle Aged
  • Maximum Tolerated Dose
  • Male
  • Lymphoma, Non-Hodgkin
  • Lung Diseases, Interstitial